Abstract
Osteoarthritis (OA) is a leading cause of chronic disability worldwide, with knee OA being the most prevalent form. Quantitative assessment of knee joint tissues using Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) has the potential to enhance OA diagnosis and progression tracking. However, current methodologies for segmenting and extracting quantitative metrics from knee joint images are time-consuming, require extensive expertise, and suffer from inter- and intra-reader variability, limiting their clinical translation.
In this study, we present and validate a fully automated AI-based pipeline for comprehensive segmentation and quantitative analysis of knee joint tissues from MRI and PET images. Our pipeline segments key joint tissues, including femoral, tibial, and patellar bones, femoral, patellar, and tibial cartilage, and medial and lateral menisci, using a deep learning-based segmentation model. Furthermore, the pipeline enables automated extraction of critical quantitative OA biomarkers, including regional cartilage thickness and T2 relaxation times, meniscus volume, a neural shape model-derived OA bone shape score, and [18F]NaF PET-based measures of subchondral bone metabolism.
To evaluate the segmentation performance, we validated automated segmentations against manual segmentations from two annotators and compared derived quantitative metrics. Results demonstrated high segmentation accuracy, with DSC values ranging from 0.84 to 0.98 across different tissues. Automated quantitative measurements exhibited good to excellent agreement with manual-derived values for most metrics, with ICC values exceeding 0.89. Our findings suggest that the proposed AI-based pipeline provides a robust, open-source tool for efficient and reproducible quantitative analysis for knee OA studies, accelerating research and clinical adoption of whole-joint quantitative imaging.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Wu Tsai Human Performance Alliance(AGoyal,AGatti), Stanford DARE (AGoyal), NIH R01AR079431 (FK), NIH AR052784 (CC), DOD W81XWH-18-1-0590 (CC), VA RX- 002452 (CC), and VA CX-002455 (CC).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Stanford University School of Medicine gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
